LenioBio GmbH, a German life sciences biotech offering a disruptive protein manufacturing technology, ALiCE®, closed its Series-A Extension round with a total investment volume of €11.5 million. The investment round, which was closed in November 2021, is led by LenioBio's current investor Bridford Group, a PE investor focusing on founder-led businesses with long-term growth potential and concerned with societal or environmental welfare.

LenioBio is a protein expression platform company committed to the advancement of transformative technology for the discovery, development, and large-scale production of proteins, unconstrained by the limitations of the cell.
LenioBio was established as a legal entity in Germany in September 2016, with offices in Dusseldorf and R&D and production labs in Aachen. For more information visit www.leniobio.com and follow LenioBio on LinkedIn.
Logo - https://mma.prnewswire.com/media/1758134/LenioBio_Logo.jpg
SOURCE LenioBio GmbH

https://www.leniobio.com/

Düsseldorf, North Rhine-Westphalia, Germany

Leniobio Closes Its Series-A Extension Round And Strengthens Its Board Of Directors

Leniobio Closes Its Series-A Extension Round And Strengthens Its Board Of Directors

Company Info